Nanotropil Novo tablets 50mg, No. 30

Diseases of the central nervous system of various origins, accompanied by a deterioration in intellectual and mnestic functions, a decrease in motor activity.

Neurotic conditions, manifested by memory impairment.

Violations of the learning process.

Psychoorganic syndromes, manifested by intellectual-mnestic disorders.

Convulsive states.

Obesity (alimentary-constitutional genesis).

Prevention of hypoxia, increasing resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and to increase mental and physical performance.

Chronic alcoholism (in order to reduce intellectual and mnestic disorders).

Inside. Take immediately after meals.

The dose and duration of treatment must be determined by the physician.

Doses vary depending on the characteristics of the patient's condition.

The average single dose is 150 mg (100 to 250 mg); the average daily dose is 250 mg (from 200 to 300 mg).

The maximum daily dose of the drug is 750 mg.

It is recommended to take a daily dose of up to 100 mg once in the morning, and over 100 mg should be divided into 2 doses.

The duration of treatment can vary from 2 weeks to 3 months, with an average of 30 days.

If necessary, the course can be repeated after 1 month.

To increase efficiency - 100-200 mg once in the morning, for 2 weeks (for athletes - 3 days).

The recommended duration of drug therapy in patients with alimentary-constitutional obesity is 30-60 days at a dose of 100-200 mg once a day (in the morning).

It is not recommended to take the drug later than 15 hours.

Active ingredient: Phenylpiracetam - 50.00 mg.

Excipients: povidone K-17, microcrystalline cellulose, sodium carboxymethyl starch, magnesium stearate.

Hypersensitivity to phonylpiracetam or any excipient in the drug.

Pregnancy and the period of breastfeeding.

Age up to 18 years (due to the lack of clinical data on the efficacy and safety of the use of phonylpiracetam in this age population).

With caution: In patients with severe organic lesions of the liver and kidneys, severe arterial hypertension, severe atherosclerosis, previous panic attacks, acute psychotic conditions proceeding with psychomotor agitation - due to the possibility of exacerbation of anxiety, panic, hallucinations and delirium, as well as in patients with allergic reactions to nootropic drugs of the pyrrolidone group.

Dosage forms

pills

International non-proprietary name: Phenylpiracetam

Composition:

Active ingredient: Phenylpiracetam - 50.00 mg.

Excipients: povidone K-17, microcrystalline cellulose, sodium carboxymethyl starch, magnesium stearate.

Pharmacological group: Nootropic drugs

Pharmacological action :

Pharmacodynamics.

A nootropic drug with a pronounced antiamnestic effect, promotes the consolidation of memory, facilitates the learning process, increases the resistance of brain tissue to toxic effects, and has an anticonvulsant effect.

It has a positive effect on metabolic processes, stimulates redox processes, increases the energy potential of the body due to the utilization of glucose.

It increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of GABA, does not bind to GABA and GABA receptors, and does not significantly affect the spontaneous bioelectric activity of the brain.

It does not affect respiration and the cardiovascular system, exhibits an unexpressed diuretic effect, and has anorexigenic activity when used as a course.

The stimulating effect is manifested in the ability to provide a moderately pronounced effect, which manifests itself in relation to motor reactions, an increase in physical performance, as well as a weakening of the severity of the hypnotic effect of ethanol and hexobarbital.

The psychostimulating effect prevails in the ideational sphere.

The adaptogenic effect is manifested in an increase in the body's resistance to stress under conditions of excessive mental and physical stress, with fatigue, hypokinesia and immobilization, at low temperatures.

Against the background of taking the drug, an improvement in vision was noted, which manifests itself in an increase in acuity, brightness and visual fields.

Improves blood flow to the lower extremities.

Stimulates the production of antibodies in response to the introduction of an antigen, which indicates immunostimulating properties, but at the same time does not contribute to the development of immediate hypersensitivity and does not change the allergic inflammatory reaction of the skin caused by the introduction of a foreign protein.

With course use, drug dependence, tolerance, 'withdrawal syndrome' do not develop.

The effect is manifested in a single dose, which is important when using the drug in extreme conditions.

Pharmacokinetics.

Absorption : Quickly absorbed. Absolute oral bioavailability is 100%.

Distribution: Penetrates into various organs and tissues, easily passes through the blood-brain barrier. The maximum concentration in the blood (Tmax) is reached after 1 hour.

Metabolism: Not metabolized in the body. Withdrawal: The half-life (T1 / 2) is 3-5 hours.

It is excreted unchanged: approximately 40% - by the kidneys and 60% - with bile and sweat.

Indications for use:

Diseases of the central nervous system of various origins, accompanied by a deterioration in intellectual and mnestic functions, a decrease in motor activity.

Neurotic conditions, manifested by memory impairment.

Violations of the learning process.

Psychoorganic syndromes, manifested by intellectual-mnestic disorders.

Convulsive states.

Obesity (alimentary-constitutional genesis).

Prevention of hypoxia, increasing resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and to increase mental and physical performance.

Chronic alcoholism (in order to reduce intellectual and mnestic disorders).

Method of administration and dosage:

Inside. Take immediately after meals.

The dose and duration of treatment must be determined by the physician.

Doses vary depending on the characteristics of the patient's condition.

The average single dose is 150 mg (100 to 250 mg); the average daily dose is 250 mg (from 200 to 300 mg).

The maximum daily dose of the drug is 750 mg.

It is recommended to take a daily dose of up to 100 mg once in the morning, and over 100 mg should be divided into 2 doses.

The duration of treatment can vary from 2 weeks to 3 months, with an average of 30 days.

If necessary, the course can be repeated after 1 month.

To increase efficiency - 100-200 mg once in the morning, for 2 weeks (for athletes - 3 days).

The recommended duration of drug therapy in patients with alimentary-constitutional obesity is 30-60 days at a dose of 100-200 mg once a day (in the morning).

It is not recommended to take the drug later than 15 hours.

Contraindications:

Hypersensitivity to phonylpiracetam or any excipient in the drug.

Pregnancy and the period of breastfeeding.

Age up to 18 years (due to the lack of clinical data on the efficacy and safety of the use of phonylpiracetam in this age population).

With caution: In patients with severe organic lesions of the liver and kidneys, severe arterial hypertension, severe atherosclerosis, previous panic attacks, acute psychotic conditions proceeding with psychomotor agitation - due to the possibility of exacerbation of anxiety, panic, hallucinations and delirium, as well as in patients with allergic reactions to nootropic drugs of the pyrrolidone group.

Application during pregnancy and during breastfeeding:

There are no data on randomized clinical trials of fonturacetam in pregnant women, therefore, the use of NanotropilЃ is new during pregnancy and breastfeeding is contraindicated.

Side effect:

Insomnia (if the drug is taken later than 15 hours). In some patients, in the first 1-3 days of admission, psychomotor agitation, hyperemia of the skin, a feeling of warmth, an increase in blood pressure are possible.

Overdose:

Overdose cases were not observed.

Treatment: symptomatic therapy.

Interaction:

Phenylpiracetam can enhance the effect of drugs that stimulate the central nervous system and nootropic drugs.

Phenylpiracetam exhibits a pronounced antagonism to the cataleptic effect of antipsychotics, and also weakens the severity of the hypnotic effect of ethanol and hexobarbital.

Special instructions:

With excessive psychoemotional exhaustion against the background of stress and fatigue, chronic insomnia, a single dose of the drug on the first day can cause a sharp need for sleep.

Such patients on an outpatient basis should be advised to start the course of taking the drug on non-working days.

Influence on the ability to drive vehicles, mechanisms:

Care should be taken when driving vehicles and mechanisms, especially in the first days of admission, given the possible occurrence of drowsiness (see 'Special instructions').

Storage conditions:

Store in a dark place, out of reach of children, at a temperature not exceeding 30 ? C.

Expiration date: 3 years.